Yong-Chan Kim
Direttore/Membro del Consiglio presso BAUDAX BIO, INC.
Patrimonio netto: 50 $ in data 30/04/2024
Profilo
Yong-Chan Kim is the founder and current Chief Executive Officer & Director of TeraImmune, Inc., which is founded in 2016.
He is also currently an Independent Director at Baudax Bio, Inc. since 2023.
Dr. Kim holds a doctorate degree from Chungnam National University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 07/09/2023 | 4 520 ( 16.69% ) | 50 $ | 30/04/2024 |
Posizioni attive di Yong-Chan Kim
| Società | Posizione | Inizio |
|---|---|---|
| BAUDAX BIO, INC. | Direttore/Membro del Consiglio | 03/07/2023 |
TeraImmune, Inc.
 TeraImmune, Inc. BiotechnologyHealth Technology TeraImmune, Inc. engages in the development of customized cell therapies for autoimmune diseases using the patient’s own Treg cells. Its pipeline includes Hemophilia A, Multiple Sclerosis, and B cell lymphoma. The company was founded by Yong-Chan Kim and Ji-Hoon Park in 2016 and is headquartered in Gaithersburg, MD. | Fondatore | 01/01/2016 |
Formazione di Yong-Chan Kim
| Chungnam National University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| BAUDAX BIO, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
TeraImmune, Inc.
TeraImmune, Inc. BiotechnologyHealth Technology TeraImmune, Inc. engages in the development of customized cell therapies for autoimmune diseases using the patient’s own Treg cells. Its pipeline includes Hemophilia A, Multiple Sclerosis, and B cell lymphoma. The company was founded by Yong-Chan Kim and Ji-Hoon Park in 2016 and is headquartered in Gaithersburg, MD. | Health Technology |
- Borsa valori
- Insiders
- Yong-Chan Kim
